ACRS News and Press, Aclaris Therapeutics Inc.

2024-07-16 16:14:56 ET More on Aclaris Therapeutics Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Therapeutics Financial information for Acla...

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...

WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...

2024-05-07 21:44:02 ET Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Results Conference Call May 07, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer ...

2024-05-07 16:04:20 ET More on Aclaris Therapeutics Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Therapeutics Financ...

- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on&#x...

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer PR Newswire CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precisi...

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Rec...